France Contraceptives Drugs Market Analysis

The France Contraceptives Drugs Market size stood at around xx Bn in 2023 and is projected to reach US $xx Bn by 2033, exhibiting a CAGR of xx% during the forecast period.

The France Contraceptives Drugs Market Analysis Executive Summary

Family planning involves the ability to control the number and the interval of children through the use of contraceptives and fertility management. Contraceptive access is vital for health and human rights; it averts unintended pregnancies, improves maternal health, reduces the demand for unsafe abortio n, and prevents mother-to-child transmission of HIV. Also, family planning helps girl education and women’s employment in the society. Yet, 214 million women in developing countries had unmet needs for contraception in 2017 for reasons such as restricted physical availability, perceived risks, cultural beliefs, lack of quality services, and gender constraints. The most common contraceptives currently in use include the combined estrogen-progesterone preparations, progesterone only preparations, and the continuous or extended use preparations. Contraceptive pills are very reliable, with a failure rate of less than 1% when used correctly with correct usage of the pill taken every day.

The birth control market is a rapidly expanding and highly specialized segment of the pharmaceuticals sector, which provides various methods and means for protecting against pregnancy and some types of STIs. Alternative methods include the pills and injections, barrier methods like the condoms and the more recent ones like the pills with no hormones and the LARCS. It is important for these products to be regulated by the FDA to guarantee that they are safe and efficient before reaching the communities. However, some of the regulatory processes such as those involved in barrier methods have been criticized for being slow and therefore slow to make new products available. Recent changes have now forced OTC vaginal contraceptives to go through intensive clinical trials and get NDAs, which might lead to a decrease in the options especially from firms that are not so big. In sum, the contraceptive market is continuously developing and faces challenges with safety and accessibility as well as challenges to its regulations.    

France Contraceptives Drugs Market Dynamics

Market Growth Drivers

Contraceptive demand worldwide especially among women of child bearing age is on the rise and is currently above 1.1 billion women requiring access to family planning, based on the WHO and UNFP estimate. Market is growing because many women are searching for suitable methods to avoid unplanned pregnancies. This is due to reduced ignorance on birth control methods in low-and middle-income countries as well as health information campaigns by non-governmental organizations as well as health facility organizations. These include the shifting away from traditional contraceptive measures such as IUDs to more effective forms such as injectable and pills, which are less likely to fail and protect against STDs. Other factors that have propelled the need for contraceptive products include fear of getting an STD and teenage unintended pregnancies. Industry players are investing in new products, mergers, and acquisitions to consolidate their positions in the market, as well as driving innovation and product development.

Opportunity

Advanced contraceptive methods, including injectables, oral tablets, and LARCs, are gaining popularity. The integration of technology, such as voice assistants for tracking, is enhancing user experience and adherence. Emerging markets like Asia-Pacific and Africa offer significant growth opportunities due to rising disposable incomes and increased government initiatives. There is also a growing interest in male contraception as social norms shift, presenting opportunities for innovation in this area. E-commerce and virtual pharmacies are creating new distribution channels, expanding access to contraceptive products, especially among younger consumers. The competitive landscape is driving companies to pursue strategic alliances, acquisitions, and R&D investments, with regulatory approvals from bodies like the FDA providing a competitive edge.

Market Restraints

There are several threats that may affect the growth of the contraceptive market. Some side effects related to the use of contraceptives include blood clotting and cardiovascular complications may reduce the likelihood of use among women with certain underlying conditions. Some of the studies carried out indicate that there is resistance to contraception due to cultural and religious factors. Lack of information on contraceptives methods or receiving wrong information can even go further in discouraging the potential users. Cost restraints, lack of funding or grants, and other financial issues may lead to difficulties in providing contraceptives and making them easily accessible, especially in low-income communities. Moreover, new types of family planning, such as natural family planning and fertility awareness, minimize the consumption of conventional birth control methods.

Competitive Landscape for Contraceptives Drugs Market in France

Key Players

• AbbVie, Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Johnson & Johnson
• Afaxys, Inc.
• Agile Therapeutics
• Viatris 
• Church & Dwight Co., Inc

Recent Developments

July 2023, U.S. FDA approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy- the first daily oral contraceptive approved for use in the U.S. without a prescription

October 2023, Two new contraceptives launched in Karnataka: Subdermal Single Rod contraceptive Implants and SC- MPA Injectable contraceptive

December 2023, The UK has begun the first trial of YCT-529, a hormone-free male contraceptive pill from YourChoice Therapeutics. This pill blocks access to vitamin A, essential for sperm production. The trial, involving 16 participants, will assess its effectiveness and safety, with results expected by June 2024. YCT-529 is 99% effective and fully reversible, representing a significant advance in male contraception.

Mergers and Acquisitions

March 2023, Reckitt Benckiser Group sold its contraception division, including popular brands like Durex, to Mankind Pharma for USD 13 million. This acquisition highlights the ongoing market consolidation as companies aim to strengthen their product portfolios and expand their market presence.

October 2023, Insud Pharma successfully closes acquisition deal for Women’s Healthcare business from Viatris

December 2023, Evofem, marketer of contraceptive gel Phexxi, sells itself to Aditxt in $100M deal

Healthcare Policies and Regulatory Landscape for Contraceptives Drugs Market in France

Policy changes and Reimbursement scenario

Some recent regulatory dynamics that have occurred in contraceptive market are as follows: FDA has shortened and then completely removed the long-term toxicology testing requirements for contraceptive drugs that are in line with other drugs. However, the restrictive policy of the FDA still hinders their efficiency in permitting the products in the market and is evident in the 6.5-year approval process for the female condom. Likewise, new regulations for over-the-counter (OTC) contraceptives gives it clinical trials and New Drug Applications (NDA) which has adverse effects on the availability of OTC contraceptives particularly to the smaller manufacturers. In developed countries, good reimbursement policies ensure that contraceptive measures get proper reimbursement hence increasing demand.